


RSC Medicinal Chemistry

rsc.li/medchem

The Royal Society of Chemistry is the world's leading chemistry community. Through our high impact journals and publications we connect the world with the chemical sciences and invest the profits back into the chemistry community.

IN THIS ISSUE

ISSN 2632-8682 CODEN RMCSCX 14(4) 585-792 (2023)



Cover
See Giuseppe Floresta, Vincenzo Abbate *et al.*, pp. 592-623.
Image designed by Salvatore Borzi and reproduced by permission of Giuseppe Floresta from *RSC Med. Chem.*, 2023, 14, 592.




Inside cover
See Jeffrey Comer *et al.*, pp. 658-670.
Image reproduced by permission of Jeffrey Comer from *RSC Med. Chem.*, 2023, 14, 658.

REVIEWS

592

Peptide-based positron emission tomography probes: current strategies for synthesis and radiolabelling


Mariacristina Failla, Giuseppe Floresta* and Vincenzo Abbate*



624

Ribosome-targeting antibiotics and resistance via ribosomal RNA methylation

Learnmore Jeremia, Benjamin E. Deprez, Debayan Dey, Graeme L. Conn* and William M. Wuest*



Editorial Staff**Executive Editor**

Rebecca Garton

Deputy Editor

Jack Washington

Editorial Production Manager

Sarah Whitehouse

Development Editor

Emily Cuffin-Munday

Publishing Editors

Nicola Burton, Tom Cozens, Katie Fernandez, Ryan Kean, Roxane Owen, Alex Rowles

Editorial Assistant

Amy Cook

Publishing Assistant

Andrea Whiteside

Publisher

Sam Keltie

For queries about submitted papers, please contact Sarah Whitehouse, Editorial Production Manager, in the first instance. E-mail medchem@rsc.org

For pre-submission queries please contact Rebecca Garton, Executive Editor. E-mail medchem-rsc@rsc.org

RSC Medicinal Chemistry (electronic: ISSN 2632-8682) is published 12 times a year by the Royal Society of Chemistry, Thomas Graham House, Science Park, Milton Road, Cambridge, UK CB4 0WF.

All orders, with cheques made payable to the Royal Society of Chemistry, should be sent to the Royal Society of Chemistry Order Department, Royal Society of Chemistry, Thomas Graham House, Science Park, Milton Road, Cambridge, CB4 0WF, UK

Tel +44 (0)1223 432398; E-mail orders@rsc.org

2023 Annual (electronic) subscription price: £1643; US\$2435. Customers in Canada will be subject to a surcharge to cover GST. Customers in the EU subscribing to the electronic version only will be charged VAT.

If you take an institutional subscription to any Royal Society of Chemistry journal you are entitled to free, site-wide web access to that journal. You can arrange access via Internet Protocol (IP) address at www.rsc.org/ip

Customers should make payments by cheque in sterling payable on a UK clearing bank or in US dollars payable on a US clearing bank.

Whilst this material has been produced with all due care, the Royal Society of Chemistry cannot be held responsible or liable for its accuracy and completeness, nor for any consequences arising from any errors or the use of the information contained in this publication. The publication of advertisements does not constitute any endorsement by the Royal Society of Chemistry or Authors of any products advertised. The views and opinions advanced by contributors do not necessarily reflect those of the Royal Society of Chemistry which shall not be liable for any resulting loss or damage arising as a result of reliance upon this material. The Royal Society of Chemistry is a charity, registered in England and Wales, Number 207890, and a company incorporated in England by Royal Charter (Registered No. RC000524), registered office: Burlington House, Piccadilly, London W1J 0BA, UK, Telephone: +44 (0) 207 4378 6556.

Advertisement sales:

Tel +44 (0) 1223 432246; Fax +44 (0) 1223 426017;

E-mail advertising@rsc.org

For marketing opportunities relating to this journal, contact marketing@rsc.org

RSC Medicinal Chemistry

rsc.li/medchem

RSC Medicinal Chemistry publishes significant research and review articles in medicinal chemistry and related drug discovery science.

Editorial Board**Editor-in-Chief**

Mike Waring, Newcastle University, UK

Associate Editors

Cynthia Dowd, George Washington University, USA

Maria Duca, Université Côte d'Azur - CNRS, France

Sally-Ann Poulsen, Griffith University, Queensland, Australia

Jian Zhang, Shanghai Jiao Tong University School of Medicine, China

Members

Hayley Binch, Hoffmann-La Roche, Switzerland

Paola Castaldi, LifeMine Therapeutics, USA

Matthew Fuchter, Imperial College London, UK

Jayanta Haldar, Jawaharlar Nehru Centre for Advanced Scientific Research, India

Lyn Jones, Dana-Farber Cancer Institute, Boston, USA

Jean-Louis Reymond, University of Bern, Switzerland

Advisory Board

Timor Baasov, Israel Institute of Technology, Israel

Andreas Bender, University of Cambridge, UK

Julian Blagg, Institute of Cancer Research, Sutton, UK

Margaret Brimble, University of Auckland, New Zealand

Mark Bunnage, Vertex Pharmaceuticals, USA

Christopher Burns, Certar Therapeutics, Australia

Andrea Cavalli, University of Bologna, Italy

Young-Tae Chang, POSTECH, South Korea

James Crawford, Genentech, Inc., USA

Matthew Duncton, Rigel Pharmaceuticals Inc, San Francisco, USA

Stephen Frye, University of North Carolina at Chapel Hill, USA

Sylvie Garneau-Tsodikova, University of Kentucky, USA

Barry Gold, University of Pittsburgh, USA

Gyoonhee Han, Yonsei University, Korea

Mike Hann, GSK Medicine Research Centre, UK

Christian Heinis, EPFL, Switzerland

Laura H. Heitman, Leiden University, Netherlands

Yoshinori Ikeura, Axcellead Drug Discovery Partners, Japan

Ahmed Kamal, NIPER, Hyderabad, India

Bob (Robert) Langer, MIT, USA

Steven V. Ley, University of Cambridge, UK

María Luz López Rodríguez, Complutense University of Madrid, Spain

Christa Müller, University of Bonn, Germany

Roberto Pellicciari, University of Perugia, Italy

David Rees, Astex Therapeutics, Cambridge, UK

Motonari Uesugi, Kyoto University, Japan

John C. Vederas, University of Alberta, Canada

Paul Wender, Stanford University, USA

Zhen Yang, Peking University, China

Ming-Qiang Zhang, Amgen, Shanghai, China

Information for Authors

Full details on how to submit material for publication in RSC Medicinal Chemistry are given in the Instructions for Authors (available from <http://www.rsc.org/authors>). Submissions should be made via the journal's homepage: rsc.li/medchem

Authors may reproduce/republish portions of their published contribution without seeking permission from the Royal Society of Chemistry, provided that any such republication is accompanied by an acknowledgement in the form: (Original Citation)–Reproduced by permission of the Royal Society of Chemistry.

This journal is © The Royal Society of Chemistry 2023.

Apart from fair dealing for the purposes of research or private study for non-commercial purposes, or criticism or review, as permitted under the Copyright, Designs and Patents Act 1988 and the Copyright and Related Rights Regulation 2003, this publication may only be reproduced, stored or transmitted, in any form or by any means, with the prior permission in writing of the Publishers or in the case of reprographic reproduction in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. US copyright law is applicable to users in the USA.

Registered Charity No. 207890.




REVIEWS

644

Recent developments of imidazo[1,2-*a*]pyridine analogues as antituberculosis agents

Sauvik Samanta, Sumit Kumar, Eswar K. Aratikatla, Sandeep R. Ghorpade and Vinayak Singh*




RESEARCH ARTICLES

658

Computational design of a cyclic peptide that inhibits the CTLA4 immune checkpoint


Ravindra Thakkar, Deepa Upreti, Susumu Ishiguro, Masaaki Tamura and Jeffrey Comer*



671

Reactive fragments targeting carboxylate residues employing direct to biology, high-throughput chemistry


Ross P. Thomas, Emma K. Grant, Eleanor R. Dickinson, Francesca Zappacosta, Lee J. Edwards, Michael M. Hann, David House, Nicholas C. O. Tomkinson* and Jacob T. Bush*



680

Synthesis and anti-proliferative activity of dehydroabietinol derivatives bearing a triazole moiety


Mingjun Zhu, Jinchuan Sun, Yaju Wu, Xianli Ma, Fuhou Lei, Qian Li,* Caina Jiang* and Fangyao Li*



692

High anti-breast cancer activities:
GI₅₀ = 0.8 - 7.3 μM
TGI = 2.04 - 18.18 μM
IC₅₀ = 5.10 - 100 μM


Very high correlation in the LC₅₀ vector with tamoxifen; high correlation in the TGI vector with Actinomycin A.



Design, synthesis and evaluation of the anti-breast cancer activity of 1,3-oxazolo[4,5-d]pyrimidine and 1,3-oxazolo[5,4-d]pyrimidine derivatives

Yevheniia Velihina,* Raey Gesese, Victor Zhirnov, Oleksandr Kobzar, Benjamin Bui, Stepan Pilyo, Andriy Vovk, Hai-Ying Shen and Volodymyr Brovarets*


700



Multi-target antibacterial mechanism of ruthenium polypyridine complexes with anthraquinone groups against *Staphylococcus aureus*

Li Jiang, Yuanyuan Ma, Yiman Chen, Mengcheng Cai, Zhixing Wu, Yanshi Xiong, Xuemin Duan,* Xiangwen Liao* and Jintao Wang*


710



Inhibition of mitochondrial metabolism by (-)-jerantinine A: synthesis and biological studies in triple-negative breast cancer cells

Timothy L. Gialelis, Zifei Wang, Joshua A. Homer, Wen-Hsuan Yang, Taemoon Chung, Qingting Hu, Christopher J. Smedley, Nitin J. Pawar, Nitinkumar S. Upadhyay, David A. Tuveson, Scott K. Lyons, Michael J. Lukey* and John E. Moses*

715



Dimeric polyphenols to pave the way for new antimalarial drugs

Gilles Degotte,* Hélène Pendeville, Carla Di Chio, Roberta Ettari, Bernard Piroette, Michel Frédéric and Pierre Francotte



